tetano
Editor, Senior Moderator
EBioMedicine
. 2024 May 8:104:105136.
doi: 10.1016/j.ebiom.2024.105136. Online ahead of print. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)
Paula David[SUP] 1 [/SUP], Saptarshi Sinha[SUP] 2 [/SUP], Khizer Iqbal[SUP] 3 [/SUP], Gabriele De Marco[SUP] 4 [/SUP], Sahar Taheri[SUP] 5 [/SUP], Ella McLaren[SUP] 2 [/SUP], Sheetal Maisuria[SUP] 6 [/SUP], Gururaj Arumugakani[SUP] 7 [/SUP], Zoe Ash[SUP] 8 [/SUP], Catrin Buckley[SUP] 3 [/SUP], Lauren Coles[SUP] 3 [/SUP], Chamila Hettiarachchi[SUP] 9 [/SUP], Emma Payne[SUP] 6 [/SUP], Sinisa Savic[SUP] 10 [/SUP], Gayle Smithson[SUP] 9 [/SUP], Maria Slade[SUP] 9 [/SUP], Rahul Shah[SUP] 3 [/SUP], Helena Marzo-Ortega[SUP] 11 [/SUP], Mansoor Keen[SUP] 8 [/SUP], Catherine Lawson[SUP] 12 [/SUP], Joanna Mclorinan[SUP] 3 [/SUP], Sharmin Nizam[SUP] 9 [/SUP], Hanu Reddy[SUP] 13 [/SUP], Omer Sharif[SUP] 14 [/SUP], Shabina Sultan[SUP] 13 [/SUP], Gui Tran[SUP] 12 [/SUP], Mark Wood[SUP] 3 [/SUP], Samuel Wood[SUP] 3 [/SUP], Pradipta Ghosh[SUP] 15 [/SUP], Dennis McGonagle[SUP] 16 [/SUP]
Affiliations
Background: Anti-MDA5 (Melanoma differentiation-associated protein-5) positive dermatomyositis (MDA5[SUP]+[/SUP]-DM) is characterised by rapidly progressive interstitial lung disease (ILD) and high mortality. MDA5 is an RNA sensor and a key pattern recognition receptor for the SARS-CoV-2 virus.
Methods: This is a retrospective observational study of a surge in MDA5 autoimmunity, as determined using a 15 muscle-specific autoantibodies (MSAs) panel, between Janurary 2018 and December 2022 in Yorkshire, UK. MDA5-positivity was correlated with clinical features and outcome, and regional SARS-CoV-2 positivity and vaccination rates. Gene expression patterns in COVID-19 were compared with autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5[SUP]+[/SUP]-DM outbreak.
Findings: Sixty new anti-MDA5+, but not other MSAs surged between 2020 and 2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022). Few (8/60) had a prior history of confirmed COVID-19, peak rates overlapped with regional SARS-COV-2 community positivity rates in 2021, and 58% (35/60) had received anti-SARS-CoV-2 vaccines. 25/60 cases developed ILD which rapidly progression with death in 8 cases. Among the 35/60 non-ILD cases, 14 had myositis, 17 Raynaud phenomena and 10 had dermatomyositis spectrum rashes. Transcriptomic studies showed strong IFIH1 (gene encoding for MDA5) induction in COVID-19 and autoimmune-ILD, but not IPF, and IFIH1 strongly correlated with an IL-15-centric type-1 interferon response and an activated CD8+ T cell signature that is an immunologic hallmark of progressive ILD in the setting of systemic autoimmune rheumatic diseases. The IFIH1 rs1990760TT variant blunted such response.
Interpretation: A distinct pattern of MDA5-autoimmunity cases surged contemporaneously with circulation of the SARS-COV-2 virus during COVID-19. Bioinformatic insights suggest a shared immunopathology with known autoimmune lung disease mechanisms.
Funding: This work was supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes of Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists.
Keywords: Autoimmune Raynauds; Autoimmune rashes; Coronavirus-19 (Covid-19); Interstitial lung disease (ILD); MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 (MIP-C); Melanoma differentiation-associated protein-5 (MDA5).
. 2024 May 8:104:105136.
doi: 10.1016/j.ebiom.2024.105136. Online ahead of print. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)
Paula David[SUP] 1 [/SUP], Saptarshi Sinha[SUP] 2 [/SUP], Khizer Iqbal[SUP] 3 [/SUP], Gabriele De Marco[SUP] 4 [/SUP], Sahar Taheri[SUP] 5 [/SUP], Ella McLaren[SUP] 2 [/SUP], Sheetal Maisuria[SUP] 6 [/SUP], Gururaj Arumugakani[SUP] 7 [/SUP], Zoe Ash[SUP] 8 [/SUP], Catrin Buckley[SUP] 3 [/SUP], Lauren Coles[SUP] 3 [/SUP], Chamila Hettiarachchi[SUP] 9 [/SUP], Emma Payne[SUP] 6 [/SUP], Sinisa Savic[SUP] 10 [/SUP], Gayle Smithson[SUP] 9 [/SUP], Maria Slade[SUP] 9 [/SUP], Rahul Shah[SUP] 3 [/SUP], Helena Marzo-Ortega[SUP] 11 [/SUP], Mansoor Keen[SUP] 8 [/SUP], Catherine Lawson[SUP] 12 [/SUP], Joanna Mclorinan[SUP] 3 [/SUP], Sharmin Nizam[SUP] 9 [/SUP], Hanu Reddy[SUP] 13 [/SUP], Omer Sharif[SUP] 14 [/SUP], Shabina Sultan[SUP] 13 [/SUP], Gui Tran[SUP] 12 [/SUP], Mark Wood[SUP] 3 [/SUP], Samuel Wood[SUP] 3 [/SUP], Pradipta Ghosh[SUP] 15 [/SUP], Dennis McGonagle[SUP] 16 [/SUP]
Affiliations
- PMID: 38723554
- DOI: 10.1016/j.ebiom.2024.105136
Background: Anti-MDA5 (Melanoma differentiation-associated protein-5) positive dermatomyositis (MDA5[SUP]+[/SUP]-DM) is characterised by rapidly progressive interstitial lung disease (ILD) and high mortality. MDA5 is an RNA sensor and a key pattern recognition receptor for the SARS-CoV-2 virus.
Methods: This is a retrospective observational study of a surge in MDA5 autoimmunity, as determined using a 15 muscle-specific autoantibodies (MSAs) panel, between Janurary 2018 and December 2022 in Yorkshire, UK. MDA5-positivity was correlated with clinical features and outcome, and regional SARS-CoV-2 positivity and vaccination rates. Gene expression patterns in COVID-19 were compared with autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5[SUP]+[/SUP]-DM outbreak.
Findings: Sixty new anti-MDA5+, but not other MSAs surged between 2020 and 2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022). Few (8/60) had a prior history of confirmed COVID-19, peak rates overlapped with regional SARS-COV-2 community positivity rates in 2021, and 58% (35/60) had received anti-SARS-CoV-2 vaccines. 25/60 cases developed ILD which rapidly progression with death in 8 cases. Among the 35/60 non-ILD cases, 14 had myositis, 17 Raynaud phenomena and 10 had dermatomyositis spectrum rashes. Transcriptomic studies showed strong IFIH1 (gene encoding for MDA5) induction in COVID-19 and autoimmune-ILD, but not IPF, and IFIH1 strongly correlated with an IL-15-centric type-1 interferon response and an activated CD8+ T cell signature that is an immunologic hallmark of progressive ILD in the setting of systemic autoimmune rheumatic diseases. The IFIH1 rs1990760TT variant blunted such response.
Interpretation: A distinct pattern of MDA5-autoimmunity cases surged contemporaneously with circulation of the SARS-COV-2 virus during COVID-19. Bioinformatic insights suggest a shared immunopathology with known autoimmune lung disease mechanisms.
Funding: This work was supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes of Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists.
Keywords: Autoimmune Raynauds; Autoimmune rashes; Coronavirus-19 (Covid-19); Interstitial lung disease (ILD); MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 (MIP-C); Melanoma differentiation-associated protein-5 (MDA5).